Company profile
BioClavis
BioClavis is a Glasgow-based R&D and service lab leveraging the proprietary TempO-Seq transcriptomic/genomic platform technology for efficient and affordable transcriptomics in precision diagnostics (including CDx development) and drug or biomarker discovery.
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQzODI4MTE3OWFkaXF6a2N4
Published 03 Oct 2024 10:04
Company registered at Companies House
1 Apr 2023 to 31 Mar 2025
Bowel cancer screening is used to find bowel cancer and pre-cancerous lesions called polyps in patients without symptoms. The aim of screening is both to catch bowel cancers early -- making them easier to treat successfully -- and to prevent cancers by removing pre-cancerous polyps. Although timings vary across the UK, adults at a certain age are invited ...
1 Jun 2022 to 29 Feb 2024
Precision medicine approaches align available therapies with patients' biology in order to provide the most suitable treatments for specific disease cases. In colorectal cancer, treatments are often prescribed which target EGFR, a biomarker present on the cell surface of cells. However, if a patients' tumour harbours certain mutations in the genes KRAS, N...
1 Feb 2021 to 31 Jul 2023
To deliver cost-effective molecular diagnostics for patients in coordination with and in context of the practical realities of today’s healthcare systems.
1 Oct 2020 to 30 Sep 2025
1 Feb 2020 to 30 Apr 2023
Public Project Summary
